Gain Therapeutics Reports Positive Phase 1b Data for Parkinson's Drug GT-02287, Plans Phase 2
GANX sits 28% above its 52-week low of $1.41 on light trading volume (0.4× avg).
Summary
Gain Therapeutics reported positive Phase 1b clinical data for GT-02287 in Parkinson's disease, showing significant biomarker reduction and clinical improvement, leading to plans for a Phase 2 trial in 2H 2026.
Key Events · Product Development and Regulatory · GANX
-
Positive Phase 1b Results for GT-02287
The company's lead program, GT-02287, completed its initial 90-day Phase 1b dosing, demonstrating positive safety and efficacy signals in Parkinson's disease patients.
-
Significant Reduction in Parkinson's Biomarker
Patients with elevated baseline CSF GluSph showed an average 81% reduction in this key biomarker to normal levels after 90 days of GT-02287 treatment (p<0.05).
-
Clinical Improvement in Motor Scores
Individuals with elevated baseline CSF GluSph also experienced a statistically significant improvement of 6.17 points in MDS-UPDRS Parts II and III scores (p<0.05).
-
Progression to Phase 2 Clinical Trial
Based on these results, Gain Therapeutics plans to initiate a Phase 2 safety and efficacy trial for GT-02287 in Parkinson's disease in the second half of 2026.
Analysis · GANX · Life Sciences
Gain Therapeutics announced positive Phase 1b clinical trial results for its lead Parkinson's disease candidate, GT-02287. The data demonstrated both significant biomarker engagement and clinical improvement, which is a crucial de-risking event for a life sciences company. The reduction in CSF GluSph and the improvement in MDS-UPDRS motor scores, particularly in patients with elevated baseline GluSph, provide strong evidence supporting the drug's disease-modifying hypothesis. This positive outcome directly supports the company's plan to initiate a Phase 2 safety and efficacy trial in the second half of 2026, marking a significant advancement for its pipeline.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 35.7% of the 1183 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GANX was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.6M. The 52-week trading range was $1.41 to $4.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.